Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?

Gülseren, Varol; Kocaer, Mustafa; Özdemir, İsa Aykut; Çakır, İlker; Şancı, Muzaffer; Güngördük, Kemal

doi:10.1016/j.currproblcancer.2019.07.003

Cited by 21 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,22,23 What's more, the combination of ER, PR, Ki67, and P53 had been demonstrated a statistically significant predictor for lymph node involvement in EC. 15 In this study, each ratio will correspond to a sensitivity and specificity, and we find the optimal cutoff value of the combined ratio ([ER + PR]/[P53 + Ki67]) by Youden…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, in clinical practice, it is lack of effectiveness and accuracy to predict the recurrence simply based on the expression of a single biomarker rather than the combined value of ER, PR, Ki67, and P53. What's more, as shown in the study on lymph node involvement of EC, the combined ratio of ([ER + PR]/[P53 + Ki67]) had been demonstrated a more statistically significant predictor than the expression of a single indicator 15 . In addition, as for EC recurrence, it is lack of research on the combined ratio of immunohistochemical markers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The combined ratio of estrogen, progesterone, Ki‐67, and P53 to predict the recurrence of endometrial cancer

Jia

Jiang

Huang

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives We aimed to explore the capacity of the combined ratio of biomarkers to predict the recurrence of Stage I–III endometrial cancer (EC). Methods A total of 473 patients were enrolled after screening. The cut‐off value of the ratio was calculated by the receiver operating characteristic curve (ROC). The univariate and multivariate Cox regression analysis was used to assess the correlation between the combined ratio and the recurrence of EC. The differences of clinicopathological parameters between the two groups divided based on the threshold were compared. Result The ROC curve showed that 0.92 was the optimal cut‐off value of the ratio ([ER + PR]/[P53 + Ki67]). The multivariate analysis demonstrated that only International Federation of Gynecology and Obstetrics stage (p = .031) and the combined ratio (p = .004) were independent risk factors of recurrence. The 3‐year recurrence‐free survival (RFS) and overall survival of patients in the low‐ratio group were 54.1% and 66.8%, respectively; while in the high‐ratio group were 94.9% and 97.9%, respectively (p < .001). The 3‐year RFS of 194 patients, who did not receive the adjuvant therapy, was 54.7% and 97.2% between two groups (p < .001). Conclusions The optimal cut‐off value (0.92) of the combined ratio was demonstrated to be better to predict the recurrence of EC than a single immunohistochemical marker.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The combined ratio of estrogen, progesterone, Ki‐67, and P53 to predict the recurrence of endometrial cancer

Jia

Jiang

Huang

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…4 Immunohistochemical markers have been widely applied in pathological reports, and have already became an important indicator for prognosis in EC and other tumors. 6,7 In breast cancer, the prognostic prediction value has been optimized by adding four immunohistochemical markers -ER, PR, HER2, and Ki67 -to the traditional model.. 8 Therefore, it is of great necessity to incorporate immunohistochemical markers into the traditional models and develop a more precise prediction model for recurrence in EC to facilitate individualized treatment for patients.…”

Section: Introductionmentioning

confidence: 99%

<p>Predicting Recurrence in Endometrial Cancer Based on a Combination of Classical Parameters and Immunohistochemical Markers</p>

Jiang

Huang

Deng

et al. 2020

CMAR

View full text Add to dashboard Cite

The aim of this study was to establish a nomogram to predict the recurrence of endometrial cancer (EC) by immunohistochemical markers and clinicopathological parameters and to evaluate the discriminative power of this model. Methods: The data of 473 patients with stages I-III endometrial cancer who had received primary surgical treatment between October 2013 and May 2018 were randomly split into two sets: a training cohort and a validation cohort at a predefined ratio of 7:3. Univariate and multivariate Cox regression analysis of screening prognostic factors were performed in the training cohort (n=332) to develop a nomogram model for EC-recurrence prediction, which was further evaluated in the validation cohort (n=141). Results: Univariate analysis found that FIGO stage, histological type, histological grade, myometrial invasion, cervical stromal invasion, postoperative adjuvant treatment, and four immunohistochemical markers (Ki67, ER, PR, and p53) were associated with recurrence in EC. Multivariate analysis showed that FIGO stage, histological type, ER, and p53 were superior parameters to generate the nomogram model for recurrence prediction in EC. Recurrence-free survival was better predicted by the proposed nomogram, with a C-index value of 0.79 (95% CI 0.66-0.92) in the validation cohort. Conclusion: This nomogram model involving immunohistochemical markers can better predict recurrence in FIGO stages I-III EC.

show abstract

“…We noticed that in some studies, the absence of ER/PR expression was also an independent predictor of poor prognosis in type II endometrial cancer. [5][6][7] Although there is a lot of literature to support that hormone receptor expression is associated with prognosis, no accepted clinical guidelines to report the role of hormone receptor status in the prognosis of endometrial cancer, but estrogen-progesterone receptors appear to be promising prognostic biomarkers in the future. 8,9 In breast cancer, ESR1 and PGR gene polymorphism was found to be related to the ER/PR expression and prognosis.…”

Section: Introductionmentioning

confidence: 99%

<p>Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer</p>

Ren¹,

Wu²,

Yin³

et al. 2020

CMAR

View full text Add to dashboard Cite

Objective In this study, 345 patients with endometrial carcinoma (EC) were selected to investigate the correlation between ER/PR status and the EC disease-free survival (DFS) rate. Methods The intensity and proportion of tumor cell expression of estrogen receptors and progesterone receptors (ER/PR) status of 345 postoperative tumor specimens in ECs were independently assessed semi-quantitatively by two pathologists using immunohistochemistry, the summed score ranged from 0 to 8 points was worked out by adding proportion score and intensity score based on the breast cancer hormone receptor immunohistochemical Allred scoring system. The association between DFS in ECs and ER/PR expression (intensity, proportion and summed score) was assessed using Cox regression analysis. Gene expression data were obtained from The Cancer Genome Atlas research network (TCGA). Results According to inclusion criteria, 201 type I and 144 type II EC patients were enrolled in this study. In the univariate analysis of type I endometrial carcinoma, the intensity, proportion and summed score of ER/PR status were significantly correlated with DFS. After adjusting for factors known to significantly impact survival, the influence of ER/PR status on DFS is generally decreased but the correlation is still significant. In the univariate analysis of type II endometrial carcinoma, the intensity, proportion and summed score of ER/PR status were significantly correlated with DFS. After adjusting for factors known to significantly impact survival, the influence of ER status on DFS is generally decreased, but the correlation is still significant, the effect of PR expression on DFS is not statistically significant. Conclusion Higher ER/PR expression status was associated with better DFS in patients with type I endometrial cancer after adjusting for known factors that significantly affect survival. In patients with type II endometrial cancer, patients with positive ER expression were significantly associated with better DFS. However, the effect of PR expression on DFS was not statistically significant.

show abstract

Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?

Cited by 21 publications

References 12 publications

The combined ratio of estrogen, progesterone, Ki‐67, and P53 to predict the recurrence of endometrial cancer

The combined ratio of estrogen, progesterone, Ki‐67, and P53 to predict the recurrence of endometrial cancer

<p>Predicting Recurrence in Endometrial Cancer Based on a Combination of Classical Parameters and Immunohistochemical Markers</p>

<p>Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer</p>

Contact Info

Product

Resources

About